Form 4: Surrozen Director Boosts Stake with $695K Stock Purchase

Surrozen Director and 10% Owner Tim Kutzkey, through affiliated funds, acquired over 36,000 shares of common stock in early December 2025.

Summary

• Tim Kutzkey, a Director and 10% Owner of Surrozen, Inc., reported indirect purchases of common stock.
• Transactions occurred on December 4, 2025, and December 5, 2025.
• A total of 36,150 shares were acquired across two affiliated entities: The Column Group III, LP and The Column Group III-A, LP.
• The shares were purchased at prices ranging from $17.347 to $19.5409 per share.
• The total value of the acquired shares is approximately $695,043.
• The purchases were made pursuant to a Rule 10b5-1(c) plan.
• Following these transactions, the indirect beneficial ownership through The Column Group III, LP increased to 869,460 shares, and through The Column Group III-A, LP increased to 981,890 shares.
• An additional 344,827 shares are indirectly held by The Column Group Opportunity III, LP.

Sentiment

Score: 8

Explanation: The significant insider buying by a director and 10% owner, totaling nearly $700,000, signals strong confidence in the company's future. While the ownership is indirect, the commitment is clear and positive for investor sentiment.

Positives

• A Director and 10% Owner, Tim Kutzkey, increased his indirect stake in Surrozen, signaling confidence in the company's future prospects.
• The total value of shares purchased was approximately $695,043, representing a significant investment.
• The transactions were executed under a Rule 10b5-1(c) plan, indicating pre-planned purchases rather than opportunistic timing.

Risks

• The beneficial ownership is indirect through various limited partnerships (The Column Group III, LP, The Column Group III-A, LP, and The Column Group Opportunity III, LP), where the reporting person is a managing partner. This structure means the reporting person disclaims beneficial ownership except to the extent of their pecuniary interest.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's future performance, but the insider purchases may be interpreted as a positive signal for future prospects.

Industry Context

Insider buying, particularly by a director and significant owner, is often viewed by the market as a strong indicator of management's confidence in the company's valuation and future performance. In the biotech sector, such signals can be particularly impactful given the long development cycles and inherent risks.

Comparison to Industry Standards

• Insider purchases, especially by a director and 10% owner, are generally seen as a positive sign of confidence, aligning with best practices for demonstrating management belief in the company's value.
• The use of a Rule 10b5-1(c) plan for these transactions is a standard practice for insiders to buy or sell shares without being accused of trading on material non-public information, providing transparency and mitigating potential legal risks.
• The magnitude of the purchase, approximately $695,043, is substantial and suggests a meaningful commitment from the reporting person, which is often compared favorably to smaller, less significant insider transactions.

Related Party Transactions

• The transactions involve the purchase of Surrozen, Inc. common stock by limited partnerships (The Column Group III, LP and The Column Group III-A, LP) where the reporting person, Tim Kutzkey, is a managing partner of their general partner. This constitutes an indirect beneficial ownership arrangement.

Stakeholder Impact

• Shareholders: Likely to view the insider purchases as a positive signal, potentially increasing confidence in the company's stock and future prospects.
• Employees: May interpret the insider buying as a sign of stability and positive outlook from leadership.
• Investment Professionals: Will likely note the significant insider investment as a factor in their analysis, potentially leading to more favorable recommendations or increased interest.

Key Dates

Recommendation

The substantial insider buying by a Director and 10% Owner, Tim Kutzkey, through affiliated funds, signals strong conviction in Surrozen's valuation and future prospects. Such a significant investment, totaling nearly $700,000, often precedes positive developments or reflects a belief that the stock is undervalued. This action by a well-informed insider provides a compelling reason for investors to consider a 'buy' position, especially given the pre-planned nature of the transactions under a Rule 10b5-1(c) plan.

Keywords

Surrozen, SRZN, Tim Kutzkey, Insider Buying, Form 4, Stock Purchase, Director, 10% Owner, Biotech, The Column Group